List of Ciprodex drug patents
Ciprodex is owned by Novartis.
Ciprodex contains Ciprofloxacin; Dexamethasone.
Ciprodex has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Ciprodex are:
- US9402805
- US9149486
- US9345714
Ciprodex was authorised for market use on 18 July, 2003.
Ciprodex is available in suspension/drops;otic dosage forms.
Ciprodex can be used as treatment of acute otitis media; treatment of acute otitis externa, treatment of acute otitis media.
The generics of Ciprodex are possible to be released after 04 June, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9402805 | NOVARTIS | Method of treating middle ear infections |
Sep, 2022
(6 months ago) | |
| US9149486 | NOVARTIS | Method of treating middle ear infections |
Sep, 2022
(6 months ago) | |
| US9345714 | NOVARTIS | Method of treating middle ear infections |
Sep, 2022
(6 months ago) | |
| US8846650 | NOVARTIS | Method of treating middle ear infections |
Jun, 2025
(2 years from now) | |
Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient
Market Authorisation Date: 18 July, 2003
Treatment: Treatment of acute otitis media; Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS;OTIC
CIPRODEX family patents
10
United States
1
Germany
1
Russia
1
Japan
1
Brazil
1
South Africa
1
Denmark
1
Austria
1
Canada
1
Mexico
1
Australia
1
Spain
1
Korea, Republic of
1
Poland
1
China
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic